Journals / Turkish Journal of Gastroenterology / 2011 / Cilt: 22 - Sayı: 2

CA 19-9’un koledok taşları ve kolanjitle ilişkisi

Relationship of CA 19-9 with choledocholithiasis and cholangitis

Pages
171–177
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In conclusion, CA 19-9 levels are associated with biliary obstruction and cholangitis but not with the number and size of stones in patients with choledocholithiasis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: It is well known that increased concentrations of CA 19-9 can be found in benign disease of the liver, pancreas and biliary tract, especially in cases with gallstone disease with cholangitis.
📊
Key Findings & Data:The aim of this study was to investigate the relation of CA 19-9 with the number and size of the stones, cholangitis and biliary obstruction in patients with choledocholithiasis.
💡
Conclusion & Impact:Conclusion: In conclusion, CA 19-9 levels are associated with biliary obstruction and cholangitis but not with the number and size of stones in patients with choledocholithiasis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: It is well known that increased concentrations of CA 19-9 can be found in benign disease of the liver, pancreas and biliary tract, especially in cases with gallstone disease with cholangitis. The aim of this study was to investigate the relation of CA 19-9 with the number and size of the stones, cholangitis and biliary obstruction in patients with choledocholithiasis. Methods: Seventy patients with radiologically proven choledocholithiasis were studied. Endoscopic retrograde cholangiopancreatography, sphincterotomy and stone extraction were applied to all patients. In each case, the parameters recorded included the levels of CA 19-9 and other laboratory tests before and after endoscopic retrograde cholangiopancreatography and the results of imaging techniques and immunoserologic tests. The correlations of these parameters were determined by SPSS 17 package program for statistical analysis. Results: Elevation of CA 19-9 was found in 32 patients (46%), while 8 patients (11%) had extraordinarily high levels (>1000 U/ml). CA 19-9 levels were correlated with serum alkaline phosphatase (r=0.5, p<0.01), gamma glutamyl transpeptidase (r=0.5, p<0.01) and bilirubin (r=0.4, p<0.01) levels but not with aspartate aminotransferase or alanine aminotransferase levels. There was also no association between serum CA 19-9 levels and the number and size of stones. Six patients had cholangitis. CA 19-9 levels were found higher in patients with cholangitis than others (100% vs. 41%, p<0.01) as well as alkaline phosphatase, gamma glutamyl transpeptidase and bilirubin levels. After stone extraction, CA 19-9 levels started to decrease and reached normal values 1-28 days later. Conclusion: In conclusion, CA 19-9 levels are associated with biliary obstruction and cholangitis but not with the number and size of stones in patients with choledocholithiasis.

Özet

Amaç: Benign karaciğer, pankreas ve özellikle kolanjitle birlikte safra taşı olan bilier sistem hastalıklarında CA 19-9’un yüksek bulunabileceği iyi bilinmektedir. Bu çalışmanın amacı, koledok taşı olan hastalarda CA 19-9 ile taşların sayı ve büyüklüğü, kolanjit ve bilier obstrüksiyon arasındaki ilişkiyi araştırmaktır. Yöntem: Radyolojik olarak koledok taşı saptanmış 70 hasta çalışmaya alındı. Hastalara endoskopik retrograd kolanjiyopankreatografi, sfinkterotomi ve taş ekstraksiyonu uygulandı. Her hastada görüntüleme sonuçları, immünoserolojik testler ve endoskopik retrograd kolanjiyopankreatografi öncesi ve sonrası bakılan CA 19-9 seviyeleri ile diğer laboratuvar tetkikleri kaydedildi. ‹statistiksel analiz için sonuçlar SPSS 17 programı kullanılarak karşılaştırıldı. Bulgular: CA 19-9 yüksekliği 32 hastada (%46) bulunurken, 8 hastada (%11) aşırı derecede yüksek seviyeler mevcuttu (> 1000 IU/ml). CA 19-9 seviyeleri, serum alkalen fosfataz (r=0.5, p<0.01), gamma glutamil transpeptidaz (r=0.5, p<0.01) ve bilirubin (r=0.4, p<0.01) seviyeleri ile korelasyon gösterirken, aspartat aminotransferaz ve alanin aminotransferaz seviyeleri ile korelasyon göstermiyordu. Serum CA 19-9 seviyeleri ile taşların sayı ve büyüklüğü arasında da bir ilişki saptanmadı. 6 hastada kolanjit vardı. Kolanjitli hastalarda CA 19-9 seviyeleri diğer gruba göre alkalen fosfataz, gamma glutamil transpeptidaz ve bilirubinde olduğu gibi daha yüksek (%100’e karşılık %41, p<0.01) bulundu. Taş ekstraksiyonundan sonra CA 19-9 seviyeleri düşmeye başladı ve 1-28 gün içinde normale döndü. Sonuç: Sonuç olarak, koledok taşı olan hastalarda yüksek serum CA 19-9 değerleri, bilier obstrüksiyon ve kolanjitle ilişkili, fakat taşların sayı ve büyüklüğü ile ilişkisizdir.

🔖

Cite This Article

DOĞAN, Ü. B., GÜMÜRDÜLÜ, Y., GÖLGE, N., KARA, B. (2011). CA 19-9’un koledok taşları ve kolanjitle ilişkisi. Turkish Journal of Gastroenterology, Cilt: 22 - Sayı: 2, 171–177. https://ajindex.com/articles/410818

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-71
  2. Paganuzii M, Onetto M, Marroni P, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988; 61: 2100-8
  3. Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker CA 19-9 in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 704-9
  4. Atkinson BF, Emst C, Herlyn M, et al. Gastrointestinal cancer associated antigen in immunoperoxidase assay. Cancer Res 1982; 42: 4820-3
  5. Arends JW, Versteynen C, Bosman FT, et al. Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma 1983; 2: 219-29
  6. Perkins GL, Slater ED, Sanders GK, et al. Serum tumour markers. Am Fam Physician 2003; 68: 1075-88
  7. Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA 19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94: 1941-6
  8. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA 19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000; 26: 474-9
  9. Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia 2003; 58: 667-72
  10. Jalanko H, Kuusela P, Roberts P, et al. Comparison of a new tumor marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984; 37: 218-22
  11. Ogawa T, Yokoi H, Kawarada Y. A case of inflammatory pseudotumor of the liver causing elevated serum CA 19-9 levels. Am J Gastroenterol 1998; 93: 2551-5
  12. Lin CL, Changchien CS, Chen YS. Mirizzi’s syndrome with a high CA 19-9 level mimicking cholangiocarcinoma. Am J Gastroenterol 1997; 92: 2309-10
  13. Turtel PS, Kreel I, Israel I, et al. Elevated CA 19-9 in a case of Mirizzi’s syndrome. Am J Gastroenterol 1992; 87: 3557
  14. Robertson AG, Davidson BR. Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA 19-9. Eur J Gastroenterol Hepatol 2007; 19: 167-9
  15. Angella S, Bouchard F, Granger P, et al. Mucinous ductal ectasia of the pancreas. J Chir (Paris) 1996; 133: 337-41
  16. Katsanos KH, Kitsanou M, Christodoulou DK, et al. High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of